• Health: The vaccine race that will save the world
  • Direct.Coronavirus Spain today, live breaking news
  • Map The incidence of Covid-19 in Spain, municipality by municipality

In the race to obtain a coronavirus vaccine, the first achievements are already visible. US pharmacist Moderna Therapeutics has released the "positive" results at an early stage of its experimental SARS-CoV-2 vaccine , which "has the potential to prevent COVID-19 disease" and will continue testing.

This means that they have passed the first phase in which the vaccine has been shown to provoke activity in the immune system . At the clinical level this is called immunogenicity and what the researchers highlight is that it has been achieved at the three prescribed dose levels. This has been achieved in the 45 voluntary participants in the trial 15 days after the injection of the molecule.

"Provisional Phase 1 data, albeit early, shows that the mRNA-1273 vaccine develops an immune response of the magnitude caused by natural infection , starting with a dose as low as 25 micrograms," the director noted in the statement. company doctor, Tal Zaks.

The nearly 50 participants in the study on the candidate vaccine mRNA-1273 , led by the US National Institute of Allergy and Infectious Diseases (NIAD), received two doses of 25, 100 and 250 micrograms and in all cases developed antibodies against COVID-19, as Moderna explains.

At this time, neutralizing antibody data is available only for the first four participants in each of the 25 micrograms and 100 micrograms dose-level cohorts. According to the antibody data, vaccination of mRNA-1273 caused neutralizing antibodies in up to eight participants, which was verified in the laboratory. The neutralizing antibody levels on day 43 were equal to or above the levels generally seen in convalescent sera .

Side effects?

MRNA-1273 was safe and well tolerated , with a safety profile already observed against infectious diseases in previous clinical studies. The only incidence of a grade 3 adverse event in was that of a participant inoculated with a 100 microgram dose who experienced grade 3 erythema (redness) around the injection site. To date, the most notable adverse events have been observed at the 250 microgram dose level, comprising three participants with systemic grade 3 symptoms, only after the second dose. All adverse events have been transient and self-resolving . There were no grade 4 or serious side effects.

In accordance with the criteria of The Trust Project

Know more

  • Science and health
  • Coronavirus
  • Covid 19
  • Vaccines
  • United States

Health''The ability to produce a vaccine is in the hands of few "

HealthGermany tests a fourth Covid-19 vaccine option in humans

Health "There are chemical substances that can lower defenses and enhance the effect of the coronavirus"